METATISSUE - BIOSOLUTIONS, LDA

Their core work

METATISSUE is a Portuguese biotech SME specializing in biofabrication and tissue engineering for regenerative medicine applications. Their core competence is developing and applying advanced manufacturing techniques — including electrospinning, photosensitive biomaterial processing, and laser-induced forward transfer (LIFT) — to produce biological scaffolds and living tissue constructs. They work with autologous biomaterials derived from human platelet lysates, meaning the tissues and scaffolds they build are designed for patient-specific transplantation without rejection risk. Within EU consortia they act as a hands-on technology contributor, bringing laboratory-scale biofabrication capability that bridges materials science and clinical application.

What they specialise in

How they've shifted over time

Both H2020 projects launched simultaneously in 2021, so there is no long-term temporal arc to trace — but the two projects do reveal a meaningful internal progression in approach. InterLynk, whose keywords dominate the early half of the dataset, sits closer to established biofabrication methods: electrospinning, photopolymerizable biomaterials, additive manufacturing of pre-formed scaffolds. UroPrint, represented by the recent-half keywords, pushes further toward frontier technology: laser-induced forward transfer of living cells and direct in vivo bioprinting, where the printer operates inside or directly on the patient. The trajectory suggests METATISSUE is building from validated scaffold fabrication methods toward real-time, in-body tissue deposition — a significant escalation in technical ambition.

METATISSUE appears to be positioning itself at the clinical frontier of biofabrication — moving from producing scaffolds in the lab toward printing functional tissue directly in living patients, which is where the highest commercial and scientific value in regenerative medicine is emerging.

How they like to work

METATISSUE has not led any H2020 project — both participations are as consortium member, indicating they prefer or are at a stage where they contribute specialist capability within larger coordinated efforts rather than driving the overall research agenda. With 14 unique partners across 6 countries spread across just 2 projects, they operate in mid-sized consortia of roughly 7 partners each, suggesting structured RIA collaborations with clear partner roles. This profile is typical of an SME that brings proprietary technology or hands-on fabrication capability that academic or clinical partners need but do not possess in-house.

METATISSUE has built a network of 14 unique partners across 6 countries through just two projects — a relatively broad geographic footprint for an SME at this scale. Their European reach spans at minimum Portugal and likely Germany, Spain, and other biomedical research hubs given the consortium composition typical of RIA grants in this domain.

What sets them apart

METATISSUE occupies a rare intersection: they combine scaffold-based biofabrication (electrospinning, photopolymerization) with active laser bioprinting capability — two distinct technology families that most organizations develop separately. As a private company rather than a university lab, they can translate these techniques toward commercial and clinical development without the bureaucratic constraints of academic IP management. For a consortium builder, they represent an SME that brings not just research participation but proprietary biofabrication process know-how that is difficult to find elsewhere in Southern Europe.

Highlights from their portfolio

• UroPrint
  One of the few EU-funded projects worldwide targeting full urinary bladder bioprinting for autologous transplantation — a high-risk, high-reward frontier combining in vivo laser cell deposition with regenerative medicine at organ scale.
• InterLynk
  The largest single grant in their portfolio (€799,836), addressing one of tissue engineering's hardest problems: repairing the interfaces between different tissue types (bone-cartilage, tendon-bone) using patient-derived platelet lysate scaffolds.